Your own T cells are collected, genetically reprogrammed to recognise your cancer, multiplied, and re-infused — a living drug that has driven complete remissions in leukaemias and lymphomas that had run out of options. China approved multiple domestic CAR-T products (the world's second-largest approved arsenal) at prices of roughly a tenth of US list prices, and runs one of the world's largest CAR-T clinical trial portfolios.
| Option | Best suited for | What it means in practice |
|---|---|---|
| Approved domestic CAR-T products (CD19) | Relapsed/refractory lymphoma and ALL | Roughly a tenth of US list prices; NMPA-approved since 2021. |
| Clinical-trial CAR-T (next-generation targets) | Cancers without approved products | China runs one of the broadest trial portfolios; screening costs nothing. |
| Allogeneic ('off-the-shelf') CAR-T trials | Patients ineligible for autologous manufacture | Emerging option, trial-based. |
| Typical China cost (reference only) | US$45,000–85,000 for an approved domestic product (including apheresis, lymphodepletion and admission); clinical-trial enrolment costs differ |
|---|---|
| Typical in-hospital stay | 2–3 weeks in hospital, plus pre-treatment work-up (2–4 weeks) |
| Return-to-travel timeline | Fly home after day-28 assessment; quarterly follow-ups can be shared with home haematology |
Costs are indicative ranges for international self-pay patients at major Chinese hospitals; final quotes depend on the hospital, implant/medication choice and case complexity. WellVoyage locks a written all-in quote before you commit.
A domestic CAR-T quote of USD 400,000 and an insurer that prevaricated. A domestically manufactured CAR-T in China at under a tenth of the price; his PET at month three shows complete metabolic response.
Third-line options at home ran out. CAR-T infusion in Shanghai after lymphodepletion; cytokine-release syndrome managed textbook-style, and she returned to London in continuous remission.
Two transplants behind him and no domestic CAR-T programme. His Almaty board had only read about the therapy; Shanghai provided it, and his follow-up scans are now measured in years of nothing happening.
A disease that relapses fast in adults. Bridging therapy, then CAR-T in Guangzhou; minimal residual disease undetectable at day 28, and her haematologist in Lyon manages the aftercare from shared records.
A complication of his kidney transplant years earlier. CAR-T in Beijing with careful immunosuppression choreography; the lymphoma melted, the kidney kept working.
Her family coordinated everything from Dubai with the hospital's international office. Apheresis, manufacturing, infusion — all in one admission; she was home for Eid in remission.
A subtype where CAR-T data are thinnest and Chinese trial experience among the deepest. Infusion in Shanghai; his first clean PET in four years arrived by WeChat before the plane home.
Cytokine release syndrome and neurotoxicity are the signature risks — fever, hypotension, confusion — which is why treatment happens inside experienced transplant units with round-the-clock management. Published Chinese series report safety profiles comparable to international registries.
Approved products today target B-cell malignancies; for other cancers the realistic path is often a clinical trial — and China's CAR-T trial portfolio is among the broadest anywhere. WellVoyage screens your records against open-protocol eligibility.
WellVoyage translates your records, obtains independent specialist opinions, and locks a transparent written quote — before you book a flight.
Start with a Free Case Review →